

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

UM-UC-3

RRID:CVCL_1783

Type: Cell Line

Proper Citation

RRID:CVCL_1783

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1783

Proper Citation: RRID:CVCL_1783

Description: Cell line UM-UC-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Bladder carcinoma

Defining Citation: [PMID:3761468](#), [PMID:7787250](#), [PMID:8873383](#), [PMID:9850064](#), [PMID:11921286](#), [PMID:12068308](#), [PMID:12127398](#), [PMID:15846775](#), [PMID:16469639](#), [PMID:18812553](#), [PMID:19375735](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25997541](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: UM-UC-3

Synonyms: UMUC-3, UM-UC3, UMUC3, UC-3, University of Michigan-Urothelial Carcinoma-3

Cross References: BTO:BTO_0003723, CLO:CLO_0009487, EFO:EFO_0006771, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1749, BioGRID_ORCS_Cell_line:444, BioSample:SAMN03471418, BioSample:SAMN03473229, BioSample:SAMN10987601, cancercellines:CVCL_1783, CancerTools:160434, CCRID:3101HUMTCHu217, Cell_Model_Passport:SIDM01182, ChEMBL-Cells:ChEMBL3307245, ChEMBL-Targets:ChEMBL612799, CLS:305074, Cosmic:715827, Cosmic:724838, Cosmic:760478, Cosmic:845568, Cosmic:846273, Cosmic:928818, Cosmic:943744, Cosmic:1046684, Cosmic:1082647, Cosmic:1285132, Cosmic:1285995, Cosmic:1302358, Cosmic:1927294, Cosmic:1938480, Cosmic:1938700, Cosmic:2050468, Cosmic:2057446, Cosmic:2212694, Cosmic:2444238, Cosmic:2700982, Cosmic-CLP:724838, DepMap:ACH-000522, ECACC:96020936, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724838, GEO:GSM136234, GEO:GSM887729, GEO:GSM888824, GEO:GSM1374978, GEO:GSM1574568, GEO:GSM1670567, IARC_TP53:377, IGRhCellID:UMUC3, KCB:KCB 2014053YJ, LiGeA:CCLE_492, LINCS_LDP:LCL-1721, PharmacDB:UMUC3_1643_2019, PRIDE:PXD003105, PRIDE:PXD030304, Progenetix:CVCL_1783, PubChem_Cell_line:CVCL_1783, Wikidata:Q54990989

ID: CVCL_1783

Record Creation Time: 20220427T221657+0000

Record Last Update: 20260920T010042+0000

Ratings and Alerts

No rating or validation information has been found for UM-UC-3.

No alerts have been found for UM-UC-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 446 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jin Z, et al. (2026) HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(1), e71388.

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. Cell reports, 45(2), 116941.

Cui S, et al. (2026) A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway in Bladder Cancer. Advanced science

(Weinheim, Baden-Wurttemberg, Germany), 13(4), e09933.

Li P, et al. (2026) TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway. *International journal of biological sciences*, 22(7), 3322.

Schmitz J, et al. (2026) Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. *Molecular oncology*, 20(3), 779.

Chen Z, et al. (2026) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. *Cell reports. Medicine*, 7(4), 102712.

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. *Molecular oncology*, 20(3), 823.

Huang Y, et al. (2026) MCUB Inhibits PRKN-Dependent Mitophagic Degradation of PD-L1 to Promote Immune Evasion in Bladder Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(5), e14764.

Shi Y, et al. (2026) piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. *Translational oncology*, 63, 102626.

Yu K, et al. (2026) Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer. *Cancer letters*, 642, 218282.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. *Cell chemical biology*, 33(6), 837.

Chen X, et al. (2025) The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression. *The FEBS journal*, 292(13), 3477.

Takemoto K, et al. (2025) DGK α Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. *Cancer medicine*, 14(5), e70710.

Osborne N, et al. (2025) Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. *Oncoimmunology*, 14(1), 2494995.

Xiong W, et al. (2025) Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. *International immunopharmacology*, 162, 115057.

Nakagawa R, et al. (2025) Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis. *Neoplasia (New York, N.Y.)*, 60, 101103.

Hatayama T, et al. (2025) Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway. *Cancer science*.

Tasaka R, et al. (2025) KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy resistance in bladder cancer by suppressing ROS accumulation.

Urologic oncology.

Li Y, et al. (2025) Comprehensive pan-cancer single-cell analysis reveals glycolysis-related signatures as predictive biomarkers for immunotherapy response and their role in bladder cancer. *International immunopharmacology*, 152, 114381.

Lee S, et al. (2024) Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. *Cell reports*, 43(5), 114146.